ClinicalTrials.gg
CompletedNCT06003049Updated Jul 17, 2024

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

A Phase 2 interventional study of OnabotulinumtoxinA and Placebo in COPD, sponsored by RMW Testing. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by RMW Testing · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
688th of 1,037
40 · median 100
Started
2023
with 33 others
Phase 2
192 of 1,278
15 open now
Registered
1,145th of 1,278
by date

Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 688th largest by enrollment of the 1,037 interventional ones that give a count, is one of 34 that started in 2023, is one of 192 in phase 2, and was the 1,145th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

The aim of this clinical trial to determine the safety and effectiveness of treating the COPD symptoms with subcutaneous BOTOX injections in participants with moderate COPD.

Read the detailed description

This is a prospective, double-blind, randomized, placebo-controlled, investigator-initiated clinical trial to assess the safety, tolerability, and efficacy using an approved drug, BOTOX, in moderate COPD participants.

Forty participants with moderate COPD, defined as mMRC Dyspnea Scale scores of grades 2 or 3 and CAT scores of 12 to 20, will be included. If eligibility criteria are met, subjects will be randomized to either the treatment arm (BOTOX) or placebo, treated on day one and observed for 90 days for safety and efficacy.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. History of moderate as diagnosed by a physician
  3. /FVC Ratio \< 0.7 with Post-Bronchodilator FEV1 ≥50% of predicted value at Screening
  4. Modified Medical Research Council (mMRC) Dyspnea Scale score of Grade 2 or 3 (Appendix B) at Screening
  5. CAT score of 12-20 (Appendix C) measured at Screening and confirmed at Baseline
  6. Ability to consent
  7. Ability to receive subcutaneous injections along the spine/back in the T-1 > T-5 region
  8. Females of must have a negative pregnancy test at screening and use of highly effective method (refer to section 12.3.9) for 4 weeks after study drug administration. Women are generally considered to be of reproductive potential if a non-menopausal female has not had a hysterectomy, bilateral oophorectomy, or medically documented ovarian failure.
  9. Males of reproductive potential must use condoms with spermicide or other methods to ensure effective contraception with partner for 4 weeks after study drug administration. Men are generally considered to be of reproductive potential if they can produce sperm.

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition that may put the participant at increased risk with exposure to botulinum toxin type A (BTX-A), including, but not limited to diagnoses of myasthenia gravis (MG), Eaton-Lambert syndrome, amyotrophic lateral sclerosis, multiple sclerosis, or any other significant disease that might interfere with neuromuscular function
  2. Treatment of study target treatment area using acupuncture, transcutaneous electrical stimulation (TENS), cranial traction or injection of anesthetics/ within 4 weeks prior to the screening visit (oral or inhaled steroids are allowed)
  3. Known allergy to BTX-A
  4. Known history of pulmonary hypertension
  5. Documented exacerbation within 4 weeks of Baseline (Day 1)
  6. Post-bronchodilator value ≤30% of the predicted value at screening
  7. Current smoker (e-cigarettes or cigarettes, cigars, pipe tobacco, vape)
  8. Prior or current lung cancer
  9. Post COVID symptoms resulting in breathing difficulties beyond pre-COVID COPD symptoms
  10. Allergy to local anesthetics
  11. History of botulism
  12. Has an active pulmonary infection requiring systemic therapy within 14 days prior to the baseline visit
  13. Known/documented medical history of clotting disorders
  14. Pregnant or breastfeeding
  15. Requires immediate admission to the hospital during screening that would render the participant unable to comply with the protocol
  16. Any serious medical condition, such as kidney, liver, or cardiac disease, asthma, angioedema, bleeding disorder, , seizure, neutropenia, AIDS, that in the judgement of the Investigator could confound study assessments
  17. Any condition (physical, mental, or social), occupational reason or other responsibility that, in the judgment of the Investigator, would jeopardize the safety or rights of the study participant, or render the participant unable to comply with the protocol, including participant's return for follow-up visits on schedule
  18. Any chronic conditions which may cause diffusion of excess of Substance P in the cerebrospinal fluid (CSF), including but not limited to diabetes, chronic kidney failure, cirrhosis, pancreatitis, osteoporosis, ongoing clinical depression, migraines and fibromyalgia, that would compromise the participant's safety as determined by the Investigator.
  19. History of keloid formation after injury.
  20. Treatment with another drug or other investigational intervention within 2 weeks of study start and throughout study duration
  21. Treatment with any botulinum toxin (BoNT) products within 6 months of the baseline visit.
  22. Any abnormal laboratory value greater than 3 times (ULN) for albumin, total protein, (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and ), and 5 times the upper limit of normal (ULN) for all other lab values.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Treatment Arm

    OnabotulinumtoxinA

    Drug: OnabotulinumtoxinA

  • Placebo comparator
    Placebo Arm

    Normal saline

    Other: Placebo

Interventions

  • BOTOX injection series

    Also known as: BOTOX

  • OtherPlacebo

    Placebo injection series

06

What researchers measure

Primary outcomes

  1. CAT (Average)

    The COPD Assessment Test (CAT) is assessed to capture the health status. The total score ranges from 0 to 40 points. Average change in CAT score over 28 days between treatment arms with a higher scores indicating a more significant change in health status.

    Time frame: 28 days

Secondary outcomes

  1. CAT (Change in Units)

    The COPD Assessment Test (CAT) is assessed to capture the health status. The total score ranges from 0 to 40 points. Portion of participants with a change in score of 2 or greater are indicating a change health status between baseline and day 28 follow-up assessment.

    Time frame: 28 days

  2. FEV1

    Percentage of predicted (% pred) of the forced expiratory volume in 1 second (FEV1). FEV1 values that are ratios that are higher than at baseline suggest an improving health status. Assessment at Baseline and day 28 follow-up assessment

    Time frame: 28 days

  3. FEV1/FVC

    Ratio of percentage of predicted (% pred) of the forced expiratory volume in 1 second to (FEV1ercentage of predicted (% pred) of the forced vital capacity (FVC). FEV1/FVC ratios that are higher than at baseline suggest an improving health status. Assessment at baseline and day 28 follow-up assessment.

    Time frame: 28 days

  4. 6MWT

    The six-minute walk test (6MWT) is performed to capture the longest 6MWT for further analyses. The longer distance covered indicates an improving health status. Assessment at baseline and day 28 follow-up assessment.

    Time frame: 28 days

  5. COPD Exacerbations

    Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. Total number of exacerbations will be analyzed and measured at baseline, all follow-up and end of trial assessments. More exacerbations experienced over time indicate a worse health status.

    Time frame: 90 days

  6. Adverse Reactions

    The number of reported adverse reactions and serious adverse events per participant. The more adverse reactions, the worse the health status of the participant measured at baseline, all follow-up and end of trial assessments.

    Time frame: 90 days

Other outcomes

  1. CAT Score

    The COPD Assessment Test (CAT) is assessed to capture the health status. The total score ranges from 0 to 40 points. Change in CAT score measured at baseline, all follow-up and end of trial assessments between treatment and placebo arms with a higher scores indicating a more significant change in health status.

    Time frame: 90 days

  2. FEV1

    Percentage of predicted (% pred) of the forced expiratory volume in 1 second (FEV1). Change in FEV1 measured at baseline, all follow-up and end of trial assessments between treatment and placebo arms with a higher scores indicating a more significant change in health status.

    Time frame: 90 days

  3. FEV1/FVC

    Ratio of percentage of predicted (% pred) of the forced expiratory volume in 1 second to (FEV1ercentage of predicted (% pred) of the forced vital capacity (FVC). FEV1/FVC measured at baseline, all follow-up and end of trial assessments between treatment and placebo arms with a higher scores indicating a more significant change in health status.

    Time frame: 90 days

  4. Vital Signs: Oxygen saturation

    Oxygen saturation (SpO2) measured at baseline, all follow-up and end of trial assessments between treatment and placebo arms with a higher scores indicating a more significant change in health status.

    Time frame: 90 days

  5. 6MWT

    The six-minute walk test (6MWT) is performed to capture the longest 6MWD for further analyses. 6MWT measured at baseline, all follow-up and end of trial assessments between treatment and placebo arms with a higher scores indicating a more significant change in health status.

    Time frame: 90 days

07

Study locations

1 site
  • Tranquil Clinical Research
    Webster, Texas 77598, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2024, 6 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 6 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 21, 2023
StartActual
Oct 1, 2023
Primary completionActual
Apr 24, 2024
CompletionActual
Jul 10, 2024
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06003049
Lead sponsor
RMW Testing
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Oct 1, 2023
Primary completion
Apr 24, 2024
Completion
Jul 10, 2024
Last update
Jul 17, 2024

Study contacts

Victoria Do
principal investigator · Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion